Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Open accessThe DOI matches its Crossref record; 98 of the 99 references it cites were found in a registry or an index.
Abstract
Benzodiazepines are some of the most commonly prescribed medications in the world. These sedative-hypnotics can provide rapid relief for symptoms like anxiety and insomnia, but are also linked to a variety of adverse effects (whether used long-term, short-term, or as needed). Many patients take benzodiazepines long-term without ever receiving evidence-based first-line treatments (e.g., psychotherapy, relaxation techniques, sleep hygiene education, serotonergic agents). This review discusses the risks and benefits of, and alternatives to benzodiazepines. We discuss evidence-based indications and contraindications, and the theoretical biopsychosocial bases for effectiveness, ineffectiveness and harm. Potential adverse effects and drug-drug interactions are summarized. Finally, both fast-acting/acute and delayed-action/chronic alternative treatments for anxiety and/or insomnia are discussed. Response to treatment—whether benzodiazepines, other pharmacological agents, or psychotherapy—should be determined based on functional recovery and not merely sedation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Benzodiazepines are commonly prescribed for anxiety and insomnia but are often misused for their sedative effects [64, 65].”
From Prevalence and patterns of substance use in West Africa: A systematic review and meta-analysis (2024) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., & Kaplan, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.807 · Cited by 2,889
Neurobiologic advances from the brain disease model of addiction
Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1511480 · Cited by 2,008
Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27286 · Cited by 1,943 · cited 10×
“However, the study [21] acknowledged the difficulty prescribers face when they “inherit” patients who previously received BZDs from other prescribers (many of whom started BZDs prior to CPGs), creating “an immediate tension” as providers attempt to balance individual patient factors with the need to provide evidence-ba…”
BackgroundInfluentialSateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519 · cited 9×
“However, the study [21] acknowledged the difficulty prescribers face when they “inherit” patients who previously received BZDs from other prescribers (many of whom started BZDs prior to CPGs), creating “an immediate tension” as providers attempt to balance individual patient factors with the need to provide evidence-ba…”
BackgroundInfluentialOpioid-induced Hyperalgesia: A Qualitative Systematic Review
Angst, M. S., & Clark, J. D. (2006) · Anesthesiology · doi:10.1097/00000542-200603000-00025 · Cited by 1,188
Substance Use Disorders in Patients With Posttraumatic Stress Disorder: A Review of the Literature
Jacobsen, L. K., Southwick, S. M., & Kosten, T. R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1184 · Cited by 1,041 · cited 1×
“High rates of comorbidity suggest that PTSD and SUDs are functionally related, a concept supported by several studies indicating a pathway (likely related to corticotropin-releasing hormone and norepinephrine) whereby PTSD precedes substance use [69].”
BackgroundFava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927 · cited 1×
“These “antidepressants” (that are not only effective for depression) typically take four to six weeks before they exert clinical effect, though in the treatment of anxiety symptoms this delay can be even longer [30].”
BackgroundComparative Meta-Analysis of Pharmacotherapy and Behavior Therapy for Persistent Insomnia
Smith, M. T., Perlis, M. L., Park, A., Smith, M. S., Pennington, J., Giles, D. E., & Buysse, D. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.5 · Cited by 863 · cited 2×
“…SAD and insomnia, BZDs are frequently overprescribed for other indications for which there is no evidence of efficacy, to individuals who have contraindicated comorbid conditions, for longer periods of time than are recommended, and before other first and second-line treatments are tried [52–57].”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Research works printed but not linked: 7
- Pary R. Lewis S. Prescribing benzodiazepines in clinical practice Resid. Staff Phys. 2008 54 8 17
- National Institute for Health and Care Excellence (NICE) Generalised Anxiety Disorder and Panic Disorder in Adults: Management 2011 Available online: https://www.nice.org.uk/guidance/cg113 (accessed on 25 October 2017) 31961629
- Stahl S.M. Essential Psychopharmacology 4th ed. Cambridge New York, NY, USA 2013
- Powers M. Becker E. Gorman J. Kissen D. Smits J. Anxiety and Depression Association of America Clinical Practice Review for GAD 2015 Available online: https:/adaa.org (accessed on 20 October 2017)
- Foa E.B. Keane T.M. Friedman M.J. Cohen J.A. Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies 2nd ed. Guilford Press New York, NY, USA 2009 566
- Ader R. Psychoneuroimmunology Elsevier Academic Press Burlington, MA, USA 2006
- Yonkers K.A. Spinelli M. Pharmacological issues during pregnancy Psychiatry 3rd ed. Tasman A. Kay J. Lieberman J.A. John Wiley & Sons Chichester, UK 2008 Volume 1 2423 2424
Cited by
Items 101–200 of 254
Coteur, K., Peters, S., Jansen, P., Schoenmakers, B., & Nuland, M. V. (2023) · Health Expectations · doi:10.1111/hex.13888 · Cited by 11
“46 Conversely, there is evidence that suggests that quality of life worsens in patients who continue or restart BZRA use in comparison to patients who stopped their intake.”
BackgroundUdi, O. A., Oyovwi, M. O., & Adeogun, A. E. (2025) · Discover Plants. · doi:10.1007/s44372-025-00127-1 · Cited by 10
“…n t l y , t h i s r e s u l t s i n b e tt e r c o g n i t i v e o u t c o m e s i n m e m o r y r e t e n t i o n a n d l e a r n i n g t a s k s [ 50 , 65 , 67 ] L e a f e x t r a c t 400 U n f a v o r a b l e a n d d e t r i m e n t a l e ff e c t s a r e o b s e r v e d , w i t h i n d i c a t…”
InfluentialA method for improved detection of 8-isoprostaglandin F2α/β and benzodiazepines in wastewater
Othman, A. A., Simpson, B. S., Jaunay, E. L., White, J. M., Bade, R., & Gerber, C. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.158061 · Cited by 7
Buard, I., Lopez‐Esquibel, N., Schoeneberger, S., Berliner, J. M., & Kluger, B. M. (2020) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000224 · Cited by 8
“However, incomplete clinical response, serious side effects, and dependence are common risks of benzodiazepines, especially with long-term use (Guina and Merrill, 2018).”
BackgroundPsychotropics and COVID-19: An analysis of safety and prophylaxis
Javelot, H., Straczek, C., Meyer, G., Faria, C. G. F., Weiner, L., Drapier, D., Fakra, É., Fossati, P., Weibel, S., Dizet, S., et al. (2021) · L Encéphale · doi:10.1016/j.encep.2021.08.002 · Cited by 6
“On the other hand, changes in current treatments that are not justified by the clinical evolution of the patient may expose patients to the following risks: (i) to decompensations of their mental health balance, potentially with all psychotropic drugs; and/or (ii) to withdrawal syndromes with benzodiazepines [20], ant…”
Warlick, H., Leon, L., Patel, R., Filoramo, S., Knipe, R., Joubran, E., Levy, A., Nguyen, H., & Rey, J. A. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-08110-9 · Cited by 6
“Benzodiazepines are heterocyclic compounds that are generally synthesized by combining a benzene ring with a diazepine ring system [11] and exhibit diverse indications, most notably insomnia and anxiety [12], by binding to the active site of GABAA receptors [13].”
BackgroundThe incidence of new and persistent benzodiazepine use after surgery
Albertsson, Þ. Í., Jónsdóttir, F., Kárason, S., & Sigurdsson, M. I. (2023) · Surgery · doi:10.1016/j.surg.2022.12.024 · Cited by 8
Hypnotic Medications as an Adjunct Treatment to Cognitive Behavioral Therapy for Insomnia
Barkopoulos, P., & Cho, H. J. (2023) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2022.10.004 · Cited by 7
Li, S., Rosen, M. C., Chang, S., David, S., & Freedman, D. J. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1213435 · Cited by 12
“Benzodiazepines, one of the most widely prescribed medications for anxiety disorders, can lead to various negative effects, including impairments in WM (Guina and Merrill, 2018).”
BackgroundDepression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Benzodiazepines at the crossroads: navigating therapeutic promise and perils of misuse
Figg, J., Love, C., Sorathia, V., Engelbart, M. K., Turner, A., & Elton, A. (2026) · Annals of General Psychiatry · doi:10.1186/s12991-025-00627-0 · Cited by 5
“GABA is the primary inhibitory neurotransmitter in the central nervous system (CNS), and this accounts for the profound hypnotic and anxiolytic effects that distinguish BZDs [32, 33] (Fig 1).”
InfluentialMa, H., & Tian, Q. (2023) · International Journal of Electrochemical Science · doi:10.1016/j.ijoes.2023.100084 · Cited by 6
Koniuszewski, F., Vogel, F. D., Dajic, I., Seidel, T., Kunze, M., Willeit, M., & Ernst, M. C. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1188101 · Cited by 8
Khan, S. M., Kasagga, A., Verma, A., Saraya, E., Haque, M. S., Senaratne, M., & Khan, S. (2025) · Cureus · doi:10.7759/cureus.84318 · Cited by 7
“Benzodiazepines can offer short-term relief from anxiety, but they are often associated with a paradoxical increase in anxiety over the long term [2].”
Krish, G., Immerman, I., & Kinjo, S. (2021) · Journal of Perioperative Practice · doi:10.1177/1750458920984048 · Cited by 9
Salazar-Fernández, C., Mawditt, C., Palet, D., Haeger, P. A., & Mella, F. R. (2022) · BMC Public Health · doi:10.1186/s12889-022-13854-x · Cited by 9
“Benzodiazepine is a psychotropic drug with sedative/ anxiolytic and hypnotic effects which acts by enhancing the effects of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the central nervous system [47].”
BackgroundAraújo, E. D. O. M., Gavioli, E. C., Holanda, V. A. D., da Silva, V. C., Messias, T. B. O. N., Dutra, L. M. G., de Oliveira, M. C., Queiroga, R. D. C. R. D. E., Guerra, G. C. B., & Soares, J. K. B. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114477 · Cited by 5
Ghabi, A., Mtiraoui, H., Amiri, N., Al-Ghulikah, H., Guerfel, T., Sanselme, M., & Hajji, M. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.136799 · Cited by 5
Karimi, F. Z., Nazari, N., Lotfi, F., Mazloom, S. R., Yousefi, M., & Rakhshandeh, H. (2024) · Sleep And Breathing · doi:10.1007/s11325-023-02979-x · Cited by 5
“Despite their effectiveness, chemical sedatives may cause various side effects [9].”
Abduljabbar, M. H., Althobaiti, M. M., Almutairi, F. M., Aldhafeeri, M. M., Aldawsari, M. F., Althobaiti, Y. S., Serag, A., & Almalki, A. H. (2025) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2025.116400 · Cited by 5
The impact of sleep medications on physical activity among diabetic older adults
Liu, Z., & Yang, C. (2019) · Geriatric Nursing · doi:10.1016/j.gerinurse.2019.12.003 · Cited by 6
Attitudes and Difficulties Associated with Benzodiazepine Discontinuation
Takeshima, M., Aoki, Y., Ie, K., Katsumoto, E., Tsuru, E., Tsuboi, T., Inada, K., Kise, M., Watanabe, K., Mishima, K., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192315990 · Cited by 7
Substance Use and Sleep Problems in Patients With Psychotic Disorders
Cederlöf, E., Torniainen‐Holm, M., Ahti, J., Lähteenvuo, M., Hietala, J. A., Häkkinen, K., Isometsä, E. T., Kampman, O., Lahdensuo, K., Lönnqvist, J. K., et al. (2022) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgac073 · Cited by 6
Benzodiazepine exposures among women of reproductive age in the US, 2004–2018
Michaels, N. L., Spiller, H., Badeti, J., Sheftall, A., Funk, A., & Smith, G. A. (2021) · Human & Experimental Toxicology · doi:10.1177/09603271211013431 · Cited by 9
Krieger, A. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1569416 · Cited by 7
Oskouei, T. E., Vatankhah, E., & Najafi, M. (2021) · Salmand · doi:10.32598/sija.16.2.3045.1 · Cited by 4
Anderson, J., & Schrift, M. J. (2022) · Seminars in Neurology · doi:10.1055/s-0041-1742144 · Cited by 4
Maladaptive coping mechanisms of sleep
Winegar, R. (2022) · The Nurse Practitioner · doi:10.1097/01.npr.0000819624.10897.33 · Cited by 4
“Benzodiazepines have been overprescribed for patients complaining of insomnia since the 1970s and are no longer recommended by sleep specialists due to their risk of dependency, abuse, and adverse reactions, including hypersomnia.(10) Opioids affect sleep effi ciency and those who take opioids on a regular basis are f…”
BackgroundNew Trends in the Methodologies of Determination of Benzodiazepine Residues in Biological Samples
Ibarra, I. S., Vázquez-Garrido, I., Islas, G., & Flores-Aguilar, J. F. (2025) · Separations · doi:10.3390/separations12040095 · Cited by 4
“The type of BDZ depends on the components present as substituents in the diazepam ring, for example, Figure 1b shows several BDZ structures and the difference in substituents are categorized as sedative, anxiolytic, anticonvulsant, and hypnotic drugs [4–6].”
Hashmi, A. M., Han, J. Y., French-Rosas, L. N., Jabbar, Q., Khan, B. A., & Shah, A. A. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180718-02 · Cited by 6
Suss, T., & Oldani, M. J. (2020) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20191218-05 · Cited by 5
Team Approach: Management of Mental Health in Orthopaedic Patients
McConaghy, K. M., Rullán, P. J., Murray, T. G., Molloy, R. M., Heinberg, L. J., & Piuzzi, N. S. (2023) · JBJS Reviews · doi:10.2106/jbjs.rvw.22.00167 · Cited by 5
The influence of new 1,2,3-triazolo-1,4-benzodiazepine derivatives on the muscle tone of rodents
Botsula, I., Kireyev, I. V., Коshovyi, O., & Chebanov, V. A. (2023) · Current issues in pharmacy and medicine science and practice · doi:10.14739/2409-2932.2023.3.287999 · Cited by 4
Sanz‐Valero, J., & Cantos-Azorín, C. (2021) · Ars Pharmaceutica (Internet) · doi:10.30827/ars.v62i4.21614 · Cited by 12
“Aparte, hay que tener en cuenta que se recomienda una duración del tratamiento de 2 a 4 semanas en insomnio y de 8 a 12 semanas en ansiedad, incluyendo en ambos casos la retirada gradual(3,37).”
BackgroundInsomnia: Will Medication Bring Rest?
Limandri, B. J. (2018) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20180619-03 · Cited by 4
Therapy of peripartum mental disorders
Stanković, M., Stojanov, J., & Antonijević, J. (2018) · AFMN Biomedicine · doi:10.5937/afmnai1904269s · Cited by 6
“In the case of obsessive-compulsive disorder which occurs during the lactation period, treatment should start with higher doses of SSRIs, specifically: sertraline (at a daily dose of up to 200 mg), fluvoxamine (at a daily dose of 300 mg), paroxetine (at a daily dose of 30-60 mg) or escitalopram (at a daily dose of up…”
BackgroundAllary, A., Proulx-Tremblay, V., Bélanger, C., Hudon, C., O’Connor, K. P., Roberge, P., Vasiliadis, H., Desrosiers, C., Cruz-Santiago, D., & Grenier, S. (2024) · Aging & Mental Health · doi:10.1080/13607863.2024.2372473 · Cited by 3
“Similar links of BZD causing or worsening depression have been made throughout the literature in the following decades (e.g. Ashton, 2002; Guina & Merrill, 2018).”
Differential effects of clonazepam on declarative memory formation and face recognition
León, C. S., Celso, A. L., Benítez, F. A. U., Bonilla, M., Olivar, N., Toledo, J., Brusco, L. I., & Forcato, C. (2024) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2024.107956 · Cited by 3
Mother's little helper turned a foe: Alprazolam use, misuse, and abuse
Cardona-Acosta, A. M., Meisser, N., Vardeleon, N. I., Steiner, H., & Bolaños‐Guzmán, C. A. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111137 · Cited by 5
Kul, A., Al, S., Dinçel, D., & Sağırlı, O. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70155 · Cited by 3
Lima, A. E., de Moura, L. C., Gomides, Y. J. B., Paes, J. F., & de Lima, R. Q. (2021) · Research Society and Development · doi:10.33448/rsd-v10i15.22886 · Cited by 7
Liu, D., Zhang, Q., Zhao, Z., Chen, M., Hou, Y., Wang, G., Shen, H., Zhu, H., Ji, Y., Ruan, L., et al. (2023) · Healthcare · doi:10.3390/healthcare11040554 · Cited by 5
Utilization of psychotropic medicines in Romania during 1998–2018
Iaru, I., Bucșa, C., Farcaş, A., Pop, C., Cristina, A., Armean, S., Brumboiu, I., Voștinaru, O., & Mogoșan, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1157231 · Cited by 5
“Nevertheless, many other factors can generally influence prescribing, but unfortunately, the available data did not permit such analysis (Riemann et al., 2017; Guina and Merrill, 2018; Ströhle et al., 2018; Delaš Aždajić et al., 2019).”
BackgroundAntoniou, T., McCormack, D., Kitchen, S. A., PAJER, K. A., Gardner, W. P., Lunsky, Y., Penner, M., Tadrous, M., Mamdani, M., Juurlink, D. N., et al. (2023) · BMC Pediatrics · doi:10.1186/s12887-023-04331-4 · Cited by 4
“…years immediately following the implementation of OHIP + is of concern, given the absence of evidence supporting long-term effectiveness for anxiety or sleep disorders and the potential for serious adverse effects, including decreased alertness, dependence, withdrawal, diversion and injury [34–36].”
BackgroundArmas, D. A., García, V. H., Castillo, Y. R., Ayala, J. R. S., Finestres, F. C., de la Torre, A. H., & Rubio, C. (2024) · Pharmacy · doi:10.3390/pharmacy12040120 · Cited by 3
“This explains why patients commonly increase dosage over time and many eventually take more than one type of BZDs after the first loses effectiveness [22].”
BackgroundA case report: Treating insomnia with olanzapine in cancer patients
Wang, Z., Tanco, K. C., Liu, E. V., Madireddy, S., Warner, K. R., & Smith, T. J. (2025) · Palliative & Supportive Care · doi:10.1017/s1478951525100345 · Cited by 3
“Benzodiazepines can be effective for both sleep onset and maintenance, but they are generally discouraged in cancer patients due to increased risk of respiratory depression with concurrent use of opioid (Guina and Merrill 2018).”
Singier, A., Carrier, H., Tournier, M., Pariente, A., Verger, P., & Salvo, F. (2021) · Therapies · doi:10.1016/j.therap.2021.09.001 · Cited by 4
O uso abusivo de benzodiazepínicos em pacientes adultos
do Nascimento, K. S., Andrade, A. C. S., Lobato, A. C. D. S., Holanda, J. A. D. S., & Castro, J. D. S. (2022) · Research Society and Development · doi:10.33448/rsd-v11i12.34076 · Cited by 9
Raffa, R. B., & Pergolizzi, J. V. (2019) · Pharmacology & Pharmacy · doi:10.4236/pp.2019.108029 · Cited by 3
“, SSRIs), there is little evidence-basis for continued use of BZDs for many conditions, and certainly not for use longer than 4 weeks (or less) [7].”
BackgroundInfluentialCarvalho-Silva, L., Jiménez‐Correa, U., Santana-Miranda, R., Heyerdahl-Viau, I., Benitez-Morales, J., García-Casas, M., & Martínez-Núñez, J. M. (2024) · Pharmacy · doi:10.3390/pharmacy12020056 · Cited by 2
“In fact, the latter is only recommended for treating insomnia when it is severe or proves to be resistant to multiple treatments [18].”
BackgroundInfluentialChirica, M. G., Adams, S. M., Quinn, P. D., Meraz, R., Rickert, M. E., Sidorchuk, A., Kroenke, K., & D'Onofrio, B. M. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.02.065 · Cited by 3
Jemere, T., van der Mei, I. A. F., Honan, C. A., Taylor, B. V., Campbell, J. A., Breslin, M. C., & Laslett, L. L. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106565 · Cited by 3
Pharmacokinetics and Residue Elimination of Diazepam in Zebrafish
Xiao, H., Li, S., Li, T., Xin, L., Liao, X., & Zhao, D. (2026) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.70044 · Cited by 2
“Benzodiazepines (BZDs) are among the most commonly prescribed psychoactive medications, primarily used to alleviate anxiety and insomnia, and for the treatment of conditions such as epileps (Guina and Merrill 2018).”
Cussotto, S., Abdennebi, S. R., Etting, I., Denny, C. A., Hen, R., Colle, R., Corruble, E., Alvarez, J., David, D. J. P., & Mendez‐David, I. (2026) · npj Biofilms and Microbiomes · doi:10.1038/s41522-026-00928-6 · Cited by 4
Снотворные средства: прошлое, настоящее, будущее
Churiukanov, V. V., & Лемина, Е. Ю. (2018) · Экспериментальная и клиническая фармакология · doi:10.30906/0869-2092-2018-81-6-40-44 · Cited by 2
Anxiolytic effect of minocycline in posttraumatic stress disorder model of Syrian hamsters
Patankar, P., Joshi, S. S., Mane, A., Manjesh, P. S., & Kokate, D. (2021) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_243_20 · Cited by 2
“Hence, there is a need for newer drugs, especially for the stage of hyperarousal and acute anxiety in PTSD [13].”
BackgroundSunshine hours and utilization of benzodiazepines
Marković, S., Nakarada, Đ. J., Mojović, M., Beljić, M., Vuković, M., & Kastratović, D. A. (2021) · Hospital Pharmacology - International Multidisciplinary Journal · doi:10.5937/hpimj2102032m · Cited by 2
“Benzodiazepines belong to the group of anxiolytic sedatives and the most prescribed drugs in the world [1].”
BackgroundThe Characteristics of Benzodiazepine Prescribing in the Republic of Srpska, Bosnia and Herzegovina
Maksimović, Ž., Stajić, M., Stojiljković, M. P., Šatara, S. S., Stojaković, N., & Škrbić, R. (2022) · Medicina · doi:10.3390/medicina58080980 · Cited by 2
Use of anxiolytics and hypnotic drugs during COVID-19 pandemic: The literature review
Trajkovski, T., & Marić, N. P. (2022) · Medicinski podmladak · doi:10.5937/mp73-35916 · Cited by 2
“), obtaining medication from several providers, or giving, selling, or trading medication to others (3).”
BackgroundInfluentialRecomendaciones y peligros del uso de las benzodiacepinas en los adultos mayores
Tinizaray, N. M. R., & Calle, D. F. C. (2023) · Revista Vive · doi:10.33996/revistavive.v6i16.224 · Cited by 4
McCracken, A., Cleverley, K., Sproule, B. A., & Dolovich, L. R. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072976 · Cited by 3
Onset of Prolonged High-Potency Benzodiazepine Use Among ICU Survivors: A Nationwide Cohort Study
Lindström, A.-C., von Oelreich, E., Eriksson, J., Eriksson, M., Mårtensson, J., Larsson, E., & Oldner, A. (2024) · Critical Care Explorations · doi:10.1097/cce.0000000000001124 · Cited by 3
“Several factors contribute to the increased likelihood of individuals being prescribed benzodiazepines, with a prominent role played by the presence of psychiatric conditions (22).”
BackgroundYang, H., Huang, Y.-C., Chiang, K.-W., Wen, Y.-L., To, S.-Y., Kao, S., & Kao, L. (2024) · Nature and Science of Sleep · doi:10.2147/nss.s491544 · Cited by 3
Wiedermann, C., Sangermano, K., Marino, P., Ausserhofer, D., Engl, A., & Piccoliori, G. (2025) · Pharmacy · doi:10.3390/pharmacy13020032 · Cited by 2
“The findings underscore the necessity for targeted interventions to optimize insomnia treatment and mitigate long-term dependence on sedative psychotropic medications, particularly benzodiazepines [23].”
Lin, M.-W., Wong, S., & Cheng, Y. (2025) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000003356 · Cited by 3
Pauwels, P., Haack, B., Toto, S., Seifert, J., Grohmann, R., Heinze, M., Zolk, O., Proskynitopoulos, P. J., Schneider, M., & Greiner, T. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00579-6 · Cited by 3
Sharifi-Rad, M., Khoobi, A., Khajeh, M., Kaykhaii, M., & Oveisi, A. R. (2025) · Scientific Reports · doi:10.1038/s41598-025-07127-x · Cited by 2
Addictophobia in modern psychiatry (benzodiazepines and other psychopharmacological drugs)
Mendelevich, В. D. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20191191275 · Cited by 3
Benzodiazepine Therapy: The Good, the Bad, and the Ugly
Guina, J., Merrill, B., & LeQuang, J. A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780197517277.003.0003 · Cited by 2
Self-citationBolt, J., Park, E., Wong, K., Lane, M., & Gorman, S. K. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00904-y · Cited by 2
“Benzodiazepines are a concern for individuals with depression as they do not prevent the development of depression, can be depressogenic and can lead to suicide attempts [21].”
BackgroundFord, J. H., Bushnell, G., Griffith, A. M., Joodi, G., Ashoka, A., Patel, N., Husain, M., Pursell, I. W., Sears, S. F., Mounsey, J. P., et al. (2021) · Psychiatric Services · doi:10.1176/appi.ps.201900389 · Cited by 3
Benzodiazepines consumptions: Influence on traffic accidents
Marković, S., Nakarada, Đ. J., Vuković, M., Mojović, M., & Kastratović, D. A. (2021) · Hospital Pharmacology - International Multidisciplinary Journal · doi:10.5937/hpimj2103073m · Cited by 2
Benzodiazepine Prescriptions for Homeless Veterans Affairs Service Users With Mental Illness
Koh, K. A., Szymkowiak, D., & Tsai, J. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20220472 · Cited by 2
Urbano, F. J., & Bisagno, V. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817992-5.00007-6 · Cited by 1
Korachi, I. B., Diouri, I., Bouaddi, O., Najdi, A., Obtel, M., Badou, A., Belyamani, L., Khalis, M., & Benjelloun, R. (2024) · BMC Medical Education · doi:10.1186/s12909-024-05825-0 · Cited by 2
Maruta, J. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1560787 · Cited by 1
Gong, J., Jia, X., Wang, L., Yiwu, L., Guo, R., Ruihan, G., Jingyu, H., Zifu, Z., Duan, S., Liu, X., et al. (2026) · Food & Function · doi:10.1039/d5fo03867g · Cited by 2
Airth, L., Goodyear, T., Marshall, B. D. L., Grant, C., Lysyshyn, M., Sherman, S. G., Wood, E., & Ti, L. (2026) · Harm Reduction Journal · doi:10.1186/s12954-025-01381-y · Cited by 2
“…to their effects on mortality, benzodiaz-epines can be prescribed as an anxiolytic and can cause a range of euphoric, hypnotic, and amnesic effects, with risks for dependence, agitation, aggression, and psychosis depending on the dose as well as individual and environmental contexts [7, 15, 18].”
Benzodiazepines for anxiety and depression: an updated overview of current use and major outcomes
Fatimi, H. E., Khalki, H., El‐Mansoury, B., Zaid, Y., & Khalki, L. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11939-z · Cited by 2
“Lorazepam and oxazepam are favored in this population by clinicians because they do not require oxidative liver metabolism and have no active metabolites, whereas the long half-lives of diazepam and clonazepam require caution [ 10].”
Essink, S. C. M., Lasys, T., Santa‐Ana‐Téllez, Y., Siiskonen, S. J., Weir, D. L., Zomerdijk, I. M., Groenwold, R. H. H., Saliete, I., Poplavska, E., Kurvits, K., et al. (2026) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2026.2671998 · Cited by 1
“This despite that the risks of benzodiazepines and BZRDs are well-described [43,46,48].”
Dougnon, G., & Ito, M. (2022) · Planta Medica · doi:10.1055/a-1770-7581 · Cited by 1
“However, these treatments vary in efficacy and tolerability and are often accompanied by severe effects and drug–drug interactions [4].”
BackgroundOlayiwola, G. (2022) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.21010/ajtcamv18i1.2 · Cited by 1
“Even within the serotoninergic receptors, 5-HT subtypes account for difference in response of animals, with some supporting anxiolysis and some not (Guina & Merrill, 2018).”
Tranquilizers/Anxiolytics: Definition, Indications, Contraindications, and Treatment
Kloiber, S. M., & Konstantinou, G. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_59 · Cited by 3
Predicting benzodiazepine prescriptions: A proof-of-concept machine learning approach
Kinney, K. L., Zheng, Y., Morris, M. C., Schumacher, J. A., Bhardwaj, S. B., & Rowlett, J. K. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1087879 · Cited by 1
“Benzodiazepines, which are associated with risk of serious adverse effects (5, 6), represent a significant public health burden (2).”
BackgroundInfluentialNavigating Alcohol Use Disorder in Adults: A Case Report
Threet, C., Tan, R. A., & Serafica, R. C. (2023) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2023.104721 · Cited by 1
Os riscos do uso abusivo de benzodiazepínicos na população idosa
Ramos, G. A., Vasconcelos, L. H. F., de Oliveira, D. F., & Duarte, N. L. (2024) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e15896.2024 · Cited by 2
USO INDISCRIMINADO DOS BENZODIAZEPÍNICOS: PAPEL DO FARMACÊUTICO PARA O USO RACIONAL
Marçal, L. M. S. F. (2024) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v5i1.5366 · Cited by 2
Association Between Non-Benzodiazepine Hypnotics and Tinnitus: A Nationwide Cohort Study in Taiwan
Lee, J.-T., Yang, H., Yu, C., Wen, Y.-L., To, S.-Y., Pan, H.-Y., & Kao, L. (2025) · Nature and Science of Sleep · doi:10.2147/nss.s545323 · Cited by 1
“5,6 Remarkably, increasing evidence suggests that GABAA receptors play a role in auditory function, and Z-drugs, which exhibit selective affinity for the α ₁ subunit, may have distinct influences on this system compared to traditional benzodiazepines.”
DRUG UTILIZATION EVALUATION OF BENZODIAZEPINES IN A TERTIARY CARE HOSPITAL
RAMA, P., Monisha, R., PAUL, S. V., Scaria, V. E., Janani, P., & Perumal, S. (2019) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2019v11i11.35359 · Cited by 1
Moffett, C., Kost, K. J., Thompson, A. L., Ossipov, M. H., Pergolizzi, J. V., Umeda‐Raffa, S., Raffa, R. B., Largent‐Milnes, T. M., & Vanderah, T. W. (2021) · Pharmacology & Pharmacy · doi:10.4236/pp.2021.125010 · Cited by 1
“125010 102 Pharmacology & Pharmacy replaced, they still carry some substantial risks [6].”
BackgroundResistant Catatonia in a 10-year-old Child: A Case Report
Jha, A. (2023) · Journal of Nepal Medical Association · doi:10.31729/jnma.8152 · Cited by 1
Pharmacological class interventions for benzodiazepine withdrawal discontinuation: a meta-analysisPreprint
Fluyau, D., Revadigar, N., Mitra, P., & Pierre, C. G. (2020) · medRxiv · doi:10.1101/2020.07.07.20148403 · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Nayanar, G. K., Tu, T. T. H., Nagamine, T., & Toyofuku, A. (2023) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2023.01.011 · Cited by 1
Haghparast, P., Nguyen, T., & Ray, S. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824315-2.00817-4 · Cited by 1
Pharmacological principles for safe benzodiazepine and Z-drug dose reduction
Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D. (2026) · Psychological Medicine · doi:10.1017/s0033291726104887
“Normal-dose physical dependence was observed from the 1960s leading to their restriction by the FDA in 1975 (Guina & Merrill, 2018; Lader, 1991).”
Saunders, J., & Galiatsatos, P. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201906-483ed
Heinemann, S. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7898 · Cited by 1
The Central Benzodiazepine Receptor
Ossipov, M. H. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780197517277.003.0005
In Search of Benzodiazepine Guidelines
LeQuang, J. A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780197517277.003.0012
Metadata
- Authors
- Guina, J., & Merrill, B.
- Affiliations
- Wright State University (US)
- Corresponding author
- Guina, Jeffrey
- ORCID
- Guina, Jeffrey
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2018-01-30
- Volume
- 7
- Issue
- 2
- Pages
- 17
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC5852433
- OpenAlex
- W2793017265
- Semantic Scholar
- 81e4137cd04cbc40756500350418397c8843db63
- Cited by
- 253
- References
- 99
- Citations by year
- 2026: 15 · 2025: 23 · 2024: 34 · 2023: 42 · 2022: 32 · 2021: 42 · 2020: 34 · 2019: 25 · 2018: 6
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Journal of Bioresource Management (submittedVersion, cc-by)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- benzodiazepines, sedative-hypnotic drugs, anxiety, insomnia, adverse effects, drug-drug interactions, long-term benzodiazepine use, psychotherapy, sleep hygiene, serotonergic agents, functional recovery, biopsychosocial model
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.